NCT06859567Not yet recruiting
Chester Step Test: is It Effective in Scleroderma Patients?
Proving the Efficacy of the Chester Step Test in Scleroderma Patients Compared with the 6-Minute Walk Test
Source: ClinicalTrials.gov · Last updated 5 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Systemic sclerosis (SSC) is a chronic autoimmune disease in which autoimmune features are associated with vascular manifestations. Patients with SSC experience many problems such as interstitial lung disease (ILD), pulmonary arterial hypertension (PAH), heart failure, severe gastrointestinal tract (GIT) involvement and scleroderma renal crisis (SRC). Because of these problems, SSC patients may develop an abnormal pulmonary hemodynamic response during exercise. In this situation, measuring the aerobic capacity of SSC patients can be a useful tool for health promotion. There are many different methods for measuring aerobic capacity tests. The most commonly used aerobic capacity test in SSC patients is the 6-minute walk test (6 MWT). However, although the 6 MWT is a commonly used test, it has some disadvantages. Because SSC affects multiple organs, there are doubts about the 6 MWT's ability to accurately assess these diseases. These disadvantages of the 6MWT have led to the search for new tests. The Chester step test (CST) is a submaximal test and a good option to assess aerobic capacity. An adapted version of the CST for non-healthy individuals can be used to assess aerobic capacity. There are some studies conducted with CST. As a result of my research, no study evaluating CST in individuals with SSC was found.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- First submitted
- 28 Feb 2025
- Start date
- 11 Mar 2025
- Primary completion date
- 15 Jun 2025
- Lead sponsor
- Firat University
- Diseases
- Systemic sclerosis (scleroderma)
- NCT number
- NCT06859567
What you commit to
- Study type: Interventional
- Planned participants: 45
- From 11 Mar 2025 to the primary completion date, 15 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Chronic obstructive pulmonary disease
- Myocardial infarction history
- Congestive heart failure
- Serious or unstable illness that may limit exercise tolerance
- Presence of severe musculoskeletal and joint disorders that may interfere with the conduct of the test
- Uncontrolled hypertension
Other
- Inability to perform the simplest level of the Chester step test
- Arthroplasty or major operations on knee and hip joints
- Lack of ability to understand and implement all recommended procedures
Who the study is looking for
- Over 18 years old
- Patients who can walk independently without an assistive device
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Firat University Coordinator of this site? Confirm its status | Merkez | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.